New hope for tough leukemia: targeted drugs join standard treatment

This study is testing whether adding specific targeted drugs to standard chemotherapy works better for adults with a hard-to-treat type of leukemia called 'Ph-like ALL.' Doctors will give patients either olverembatinib or ruxolitinib based on their specific genetic test results, alongside chemotherapy and another drug called venetoclax. The main goal is to see if this combination can get patients into a deep remission with no detectable cancer cells after three months of treatment.